Group 1 - The core point of the news is that Huahao Zhongtian Pharmaceutical-B (02563.HK) announced the completion of the first patient dosing in a significant overseas clinical study for UTD1 combined with capecitabine to treat HER2-negative breast cancer brain metastases (BCBM) in the United States [1] Group 2 - The study is designed in two phases, aiming to enroll approximately 120 subjects, with the primary endpoint being the central nervous system objective response rate (CNS-ORR) [2] - The research involves nearly 20 leading research centers across the United States, including MD Anderson Cancer Center, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, City of Hope-Duarte, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Colorado Hospital, Augusta University, and University of California Los Angeles [2]